Zobrazeno 1 - 10
of 269
pro vyhledávání: '"David F. Claxton"'
Autor:
Johnson Ung, Su-Fern Tan, Todd E. Fox, Jeremy J. P. Shaw, Maansi Taori, Bethany J. Horton, Upendarrao Golla, Arati Sharma, Zdzislaw M. Szulc, Hong-Gang Wang, Charles E. Chalfant, Myles C. Cabot, David F. Claxton, Thomas P. Loughran, David J. Feith
Publikováno v:
Cancers, Vol 15, Iss 24, p 5866 (2023)
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously determined that ac
Externí odkaz:
https://doaj.org/article/2b10d02d3df14a2fa425f31c45b24ad7
Autor:
Fenghua Qian, Shaneice K. Nettleford, Jiayan Zhou, Brooke E. Arner, Molly A. Hall, Arati Sharma, Charyguly Annageldiyev, Randy M. Rossi, Diwakar B. Tukaramrao, Deborpita Sarkar, Shailaja Hegde, Ujjawal H. Gandhi, Emily R. Finch, Laura Goodfield, Michael D. Quickel, David F. Claxton, Robert F. Paulson, K. Sandeep Prabhu
Publikováno v:
Cell Reports, Vol 42, Iss 7, Pp 112794- (2023)
Summary: Relapse of acute myeloid leukemia (AML) remains a significant concern due to persistent leukemia-initiating stem cells (LICs) that are typically not targeted by most existing therapies. Using a murine AML model, human AML cell lines, and pat
Externí odkaz:
https://doaj.org/article/ce35a814bf814b97aa20a01a202f9e01
Autor:
Chenchen Zhao, Matthew Bartock, Bei Jia, Neal Shah, David F. Claxton, Baldeep Wirk, Kevin L. Rakszawski, Myles S. Nickolich, Seema G. Naik, Witold B. Rybka, W Christopher C. Ehmann, Raymond J. Hohl, Jessica Valentin, Michelle Bernas-Peterson, Emily M. Gerber, Michele Zimmerman, Joseph A. Mierski, Shin Mineishi, Hong Zheng
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-7 (2022)
Abstract Despite the increased usage of post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation (allo-HSCT), our knowledge of immune reconstitution post-allo-HSCT in the setting of PTCy is limited. Adequate immun
Externí odkaz:
https://doaj.org/article/bfea2784d4844593904fbd9782851e9c
Autor:
Kelsey H. Fisher-Wellman, Miki Kassai, James T. Hagen, P. Darrell Neufer, Mark Kester, Thomas P. Loughran, Charles E. Chalfant, David J. Feith, Su-Fern Tan, Todd E. Fox, Johnson Ung, Gemma Fabrias, Jose’ Luis Abad, Arati Sharma, Upendarrao Golla, David F. Claxton, Jeremy J. P. Shaw, Debajit Bhowmick, Myles C. Cabot
Publikováno v:
Cancers, Vol 15, Iss 6, p 1883 (2023)
Acute myelogenous leukemia (AML), the most prevalent acute and aggressive leukemia diagnosed in adults, often recurs as a difficult-to-treat, chemotherapy-resistant disease. Because chemotherapy resistance is a major obstacle to successful treatment,
Externí odkaz:
https://doaj.org/article/ca6bd77bb8654ba79e7f98395933d8b2
Autor:
Li-Pin Kao, Samy A.F. Morad, Traci S. Davis, Matthew R. MacDougall, Miki Kassai, Noha Abdelmageed, Todd E. Fox, Mark Kester, Thomas P. Loughran, Jr., Jose' L. Abad, Gemma Fabrias, Su-Fern Tan, David J. Feith, David F. Claxton, Sarah Spiegel, Kelsey H. Fisher-Wellman, Myles C. Cabot
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 9, Pp 1590-1602 (2019)
The combination of daunorubicin (dnr) and cytarabine (Ara-C) is a cornerstone of treatment for acute myelogenous leukemia (AML); resistance to these drugs is a major cause of treatment failure. Ceramide, a sphingolipid (SL), plays a critical role in
Externí odkaz:
https://doaj.org/article/fd54fe2e27784a42b78f98d42562f8fa
Autor:
Su-Fern Tan, Wendy Dunton, Xin Liu, Todd E. Fox, Samy A.F. Morad, Dhimant Desai, Kenichiro Doi, Mark R. Conaway, Shantu Amin, David F. Claxton, Hong-Gang Wang, Mark Kester, Myles C. Cabot, David J. Feith, Thomas P. Loughran, Jr.
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 6, Pp 1078-1086 (2019)
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. More than half of older AML patients fail to respond to cytotoxic chemotherapy, and most responders relapse with drug-resistant disease. Failure to achieve complete remission c
Externí odkaz:
https://doaj.org/article/a185154e7e4d47c99c08cbdef0bdcbba
Autor:
Yaxian Kong, Bei Jia, Chenchen Zhao, David F. Claxton, Arati Sharma, Charyguly Annageldiyev, Joseph S. Fotos, Hui Zeng, Robert F. Paulson, K. Sandeep Prabhu, Hong Zheng
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-11 (2019)
Abstract Background Successful treatment for acute myeloid leukemia (AML) remains challenging. Inhibiting immune checkpoint to enhance anti-tumor response is an attractive strategy for effective leukemia therapeutics. CD73 is a recently recognized im
Externí odkaz:
https://doaj.org/article/0af86c29d57640ac8a9139d616b7bb2e
Autor:
Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Neil D. Palmisiano, Ming Wang, Bei Jia, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hui Zeng, Hong Zheng
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-13 (2017)
Abstract Background T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) and programmed cell death protein 1 (PD-1) are important inhibitory receptors that associate with T cell exhaustion in acute myeloid le
Externí odkaz:
https://doaj.org/article/58d71e23b53049f58def55e2864a4e4f
Autor:
Kathleen M. Kokolus, Jeremy S. Haley, Emily J. Koubek, Raghavendra Gowda, Saketh S. Dinavahi, Arati Sharma, David F. Claxton, Klaus F. Helm, Joseph J. Drabick, Gavin P. Robertson, Jeffrey D. Neighbors, Raymond J. Hohl, Todd D. Schell
Publikováno v:
OncoImmunology, Vol 8, Iss 2 (2019)
Metastatic melanoma is a significant clinical problem with a 5-year survival rate of only 15–20%. Recent approval of new immunotherapies and targeted inhibitors have provided much needed options for these patients, in some cases promoting dramatic
Externí odkaz:
https://doaj.org/article/5046be52e262417b833f22a08b249b8a
Autor:
Liru Wang, Bei Jia, David F. Claxton, W Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Treatment of acute myeloid leukemia (AML) remains challenging. Enhancement of anti-tumor responses by blocking negative immune regulators is a promising strategy for novel effective leukemia therapeutics. V-domain Ig suppressor of T-cell activation (
Externí odkaz:
https://doaj.org/article/61d6bff65ad14a288a8141619644fce2